ReviewGynecology and pelvic medicine2025
Hormonal and complimentary treatments for endometriosis: a narrative review.
Review in Gynecology and pelvic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Precision Therapeutic and Preventive Molecular Strategies for Endometriosis-Associated Infertility.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Endometriosis causes infertility and pain and is associated with detriment to quality of life. The aim is to review hormonal and complementary treatments for pain in women with endometriosis. Up until this review was registered on PROSPERO, no other review had focused exclusively on hormonal and complementary treatments for endometriosis. Prior reviews broadly covered surgical, hormonal, and complementary treatments. Methods: This narrative review was carried out by searching the PubMed, Virtual Health Library and Embase databases for publications in English or Portuguese from 2014 to 2024 about hormonal and complementary treatments. Studies were selected if they focused on endometriosis treatment and a pain scale or quality of life questionnaire were specified. Key Content and Findings: A total of 1,201 publications were identified. After excluding duplications and applying inclusion criteria, 48 studies remained, of which 33 were selected for this review. Dienogest is the most studied therapy, with evidence of its use as first-line treatment. Combined oral pills were superior to placebo and have comparable efficacy to dienogest. Gonadotropin-releasing hormone (GnRH) agonists should be prescribed on a short-term basis, as second-line treatment, considering the side effects, impacts on bone mineral density and cardiovascular health. GnRH antagonists represent a promising therapy, due to dose-dependent hypoestrogenism, minimizing side effects compared to agonists. However, they have not been compared to first-line treatments and so far, should be reserved for cases of treatment failure. Findings suggest that complementary therapies seem to have an important role in adjuvant pain control. However, it is difficult to assess the isolated effect of these therapies because the studies involve multiple concurrent interventions and are not placebo-controlled. Conclusions: Progestins and combined oral contraceptive pills are first-line treatments and GnRH analogues are second-line treatments according to studies with good quality evidence. Complementary treatments lack good quality evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.